• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

患者的人口统计学和社会经济学特征影响着银屑病的治疗决策过程。

Patients' demographic and socioeconomic characteristics influence the therapeutic decision-making process in psoriasis.

机构信息

Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.

Department of Medicine and Aging Science, Dermatologic Clinic, G. D'Annunzio University, Chieti-Pescara, Chieti, Italy.

出版信息

PLoS One. 2020 Aug 12;15(8):e0237267. doi: 10.1371/journal.pone.0237267. eCollection 2020.

DOI:10.1371/journal.pone.0237267
PMID:32785291
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7423114/
Abstract

BACKGROUND

Knowledge regarding differences in care for psoriatic patients is limited. The aim of this study was to investigate factors influencing prescription of systemic treatments for patients with psoriasis with a special focus on socioeconomic factors.

METHODS AND FINDINGS

This was a non-interventional, cross-sectional study, conducted in 18 Italian University and/or hospital centers with psoriasis-specialized units. Questionnaires evaluating demographic and socioeconomic characteristics were administered to participants. Overall, 1880 consecutive patients affected by mild-to-severe psoriasis were recruited. Univariate and multivariable logistic regression analyses of systemic therapy prescription, with a special focus on biologics, accounting for the above mentioned characteristics were performed. Our analysis showed that all analyzed patients' characteristics were significantly associated with biological therapy compared to non-biological systemic one. Particularly, women were less likely to receive biologics than men (OR = 0.66; 95% CI, 0.57-0.77). Elderly patients (≥65 years) and subjects with a BMI ≥30 had lower odds to receive biologics respect to adults (≥35-64 years) (OR = 0.33; 95% CI, 0.25-0.40), and subjects with BMI≥25<30 (OR = 0.64; 95% CI, 0.53-0.77), respectively. Northern and Southern patients were both less likely to receive biologics than Central patients (OR = 0.75; 95% CI, 0.63-0.89, and OR = 0.56; 95% CI,0.47-0.68, respectively). Lower economic profile and never reading books were both associated with decreased odds of receiving biological therapy.

CONCLUSIONS

This study shows that sex, age, comorbidities, and socioeconomic characteristics influence the prescription of systemic treatments in psoriasis, highlighting that there are still unmet needs influencing the therapeutic decision-making process that have to be addressed.

摘要

背景

关于银屑病患者护理差异的知识有限。本研究旨在调查影响银屑病患者系统治疗处方的因素,特别关注社会经济因素。

方法和发现

这是一项非干预性、横断面研究,在 18 家意大利大学和/或医院中心的银屑病专科单位进行。向参与者发放评估人口统计学和社会经济特征的问卷。共招募了 1880 名患有轻至重度银屑病的连续患者。对系统治疗处方进行单变量和多变量逻辑回归分析,特别关注生物制剂,并考虑到上述特征。我们的分析表明,与非生物制剂相比,所有分析患者的特征均与生物制剂显著相关。特别是,女性接受生物制剂的可能性低于男性(OR=0.66;95%CI,0.57-0.77)。老年患者(≥65 岁)和 BMI≥30 的患者接受生物制剂的可能性低于成年人(≥35-64 岁)(OR=0.33;95%CI,0.25-0.40),以及 BMI≥25<30 的患者(OR=0.64;95%CI,0.53-0.77)。北部和南部的患者接受生物制剂的可能性均低于中部的患者(OR=0.75;95%CI,0.63-0.89,和 OR=0.56;95%CI,0.47-0.68)。经济状况较低和从不读书均与接受生物制剂治疗的可能性降低相关。

结论

本研究表明,性别、年龄、合并症和社会经济特征影响银屑病的系统治疗处方,突出表明仍存在影响治疗决策过程的未满足需求,需要加以解决。

相似文献

1
Patients' demographic and socioeconomic characteristics influence the therapeutic decision-making process in psoriasis.患者的人口统计学和社会经济学特征影响着银屑病的治疗决策过程。
PLoS One. 2020 Aug 12;15(8):e0237267. doi: 10.1371/journal.pone.0237267. eCollection 2020.
2
Inequalities in access to biological treatments for psoriasis: results from the Italian Psocare registry.意大利 Psocare 登记研究:银屑病生物治疗获得情况的不平等。
Br J Dermatol. 2017 May;176(5):1331-1338. doi: 10.1111/bjd.15234. Epub 2017 Apr 5.
3
Biologic agents perception in patients attending for the first-time to psoriasis centers: a multicenter Italian survey.首次到银屑病中心就诊的患者对生物制剂的认知:一项多中心的意大利调查。
G Ital Dermatol Venereol. 2020 Apr;155(2):150-154. doi: 10.23736/S0392-0488.17.05754-6. Epub 2017 Nov 30.
4
Quality of life and related factors in a cohort of plaque-type psoriasis patients in La Coruña, Spain.西班牙拉科鲁尼亚斑块型银屑病患者队列中的生活质量及相关因素
Int J Dermatol. 2014 Nov;53(11):e507-11. doi: 10.1111/ijd.12294. Epub 2014 Sep 30.
5
[Psoriatic patients: Analysis of patients dissatisfied with their management].[银屑病患者:对治疗不满的患者分析]
Ann Dermatol Venereol. 2017 Aug-Sep;144(8-9):497-507. doi: 10.1016/j.annder.2017.03.025. Epub 2017 Jun 16.
6
Biologic and Conventional Systemic Therapies Show Similar Safety and Efficacy in Elderly and Adult Patients With Moderate to Severe Psoriasis.生物疗法和传统全身疗法在中重度银屑病老年和成年患者中显示出相似的安全性和疗效。
J Drugs Dermatol. 2015 Aug;14(8):846-52.
7
The association of socioeconomic and clinical characteristics with health-related quality of life in patients with psoriasis: a cross-sectional study.社会经济和临床特征与银屑病患者健康相关生活质量的相关性:一项横断面研究。
Health Qual Life Outcomes. 2018 Sep 12;16(1):180. doi: 10.1186/s12955-018-1007-7.
8
Healthcare Provider Type and Switch to Biologics in Psoriasis: Evidence from Real-World Practice.医疗机构类型与银屑病生物制剂转换:来自真实世界实践的证据。
BioDrugs. 2016 Apr;30(2):145-51. doi: 10.1007/s40259-016-0163-8.
9
Latent tuberculosis infection in patients with chronic plaque psoriasis: evidence from the Italian Psocare Registry.意大利 Psocare 注册研究:慢性斑块状银屑病患者的潜伏性结核感染证据。
Br J Dermatol. 2015 Jun;172(6):1613-1620. doi: 10.1111/bjd.13539. Epub 2015 Mar 17.
10
Factors associated with the prescription of "traditional" or "biological" systemic treatment in psoriasis.银屑病中与“传统”或“生物”全身治疗处方相关的因素。
J Dermatolog Treat. 2015 Feb;26(1):37-40. doi: 10.3109/09546634.2013.878449. Epub 2014 Feb 7.

引用本文的文献

1
Targeting Cytokine Dysregulation in Psoriasis: The Role of Dietary Interventions in Modulating the Immune Response.针对银屑病中的细胞因子失调:饮食干预在调节免疫反应中的作用。
Int J Mol Sci. 2025 Mar 22;26(7):2895. doi: 10.3390/ijms26072895.
2
Real-Life Analysis of Therapeutic Management and Its Correlation with the Dermatology Life Quality Index Score in 108 Patients with Pustular Psoriasis: An Italian Monocenter Study.108例脓疱型银屑病患者治疗管理的真实生活分析及其与皮肤病生活质量指数评分的相关性:一项意大利单中心研究
Dermatol Pract Concept. 2025 Jan 30;15(1):4871. doi: 10.5826/dpc.1501a4871.
3
TELEPROM Psoriasis: Enhancing patient-centered care and health-related quality of life (HRQoL) in moderate-to-severe plaque psoriasis.

本文引用的文献

1
Ixekizumab Effectiveness and Safety in the Treatment of Moderate-to-Severe Plaque Psoriasis: A Multicenter, Retrospective Observational Study.依奇珠单抗治疗中重度斑块状银屑病的疗效和安全性:一项多中心、回顾性观察研究。
Am J Clin Dermatol. 2020 Jun;21(3):441-447. doi: 10.1007/s40257-019-00490-2.
2
Efficacy and safety of ixekizumab in a group of 16 elderly patients with psoriasis over a 1-year period.16例老年银屑病患者使用司库奇尤单抗1年的疗效和安全性。
J Eur Acad Dermatol Venereol. 2020 Mar;34(3):e152-e153. doi: 10.1111/jdv.16063. Epub 2020 Jan 19.
3
Treatment decisions in psoriasis.
远程促进银屑病治疗:改善中重度斑块状银屑病以患者为中心的护理及健康相关生活质量(HRQoL)
Front Med (Lausanne). 2024 Dec 10;11:1465725. doi: 10.3389/fmed.2024.1465725. eCollection 2024.
4
A systematic review of sex and gender differences in treatment outcome of inflammatory skin diseases: Is it time for new guidelines?炎症性皮肤病治疗结果中性别差异的系统评价:是时候制定新指南了吗?
J Eur Acad Dermatol Venereol. 2025 Mar;39(3):512-528. doi: 10.1111/jdv.20256. Epub 2024 Jul 30.
5
Factors associated with a better treatment efficacy among psoriasis patients: a study based on decision tree model and logistic regression in Shanghai, China.与银屑病患者治疗效果更好相关的因素:基于决策树模型和 logistic 回归的在中国上海开展的研究。
BMC Public Health. 2024 Jul 18;24(1):1934. doi: 10.1186/s12889-024-19468-9.
6
The Influence of Socioeconomic Factors on Access to Biologics in Psoriasis.社会经济因素对银屑病患者生物制剂可及性的影响
J Clin Med. 2023 Nov 22;12(23):7234. doi: 10.3390/jcm12237234.
7
Healthy Habits Factors and Stress Associated with Health-Related Quality of Life in a Peruvian Adult Population: A Cross-Sectional Study.秘鲁成年人群中与健康相关生活质量相关的健康习惯因素及压力:一项横断面研究。
J Multidiscip Healthc. 2023 Sep 12;16:2691-2700. doi: 10.2147/JMDH.S412962. eCollection 2023.
8
Criteria used to define tumor necrosis factor-alpha inhibitors failure in patients with moderate-to-severe psoriasis: a systematic literature review.用于定义中重度银屑病患者肿瘤坏死因子-α抑制剂治疗失败的标准:系统文献回顾。
Ann Med. 2023 Dec;55(1):1335-1345. doi: 10.1080/07853890.2023.2192957.
9
The Impact of Psoriasis and Atopic Dermatitis on Quality of Life: A Literature Research on Biomarkers.银屑病和特应性皮炎对生活质量的影响:生物标志物的文献研究
Life (Basel). 2022 Dec 5;12(12):2026. doi: 10.3390/life12122026.
10
Habits of Using Social Media and the Internet in Psoriasis Patients.银屑病患者使用社交媒体和互联网的习惯
Dermatol Pract Concept. 2022 Jul 1;12(3):e2022143. doi: 10.5826/dpc.1203a143. eCollection 2022 Jul.
银屑病的治疗决策
J Comp Eff Res. 2019 Sep;8(12):947-949. doi: 10.2217/cer-2019-0090. Epub 2019 Sep 12.
4
Biologics exposure during pregnancy and breastfeeding in a psoriasis patient.银屑病患者在妊娠和哺乳期接触生物制剂。
Dermatol Ther. 2019 May;32(3):e12895. doi: 10.1111/dth.12895. Epub 2019 Apr 17.
5
Psoriasis, Cardiovascular Events, and Biologics: Lights and Shadows.银屑病、心血管事件和生物制剂:利弊共存。
Front Immunol. 2018 Aug 13;9:1668. doi: 10.3389/fimmu.2018.01668. eCollection 2018.
6
Elderly psoriatic patients under biological therapies: an Italian experience.生物疗法治疗下的老年银屑病患者:意大利经验。
J Eur Acad Dermatol Venereol. 2019 Jan;33(1):143-146. doi: 10.1111/jdv.15139. Epub 2018 Jul 6.
7
Real-life effectiveness of biological drugs on psoriatic difficult-to-treat body regions: scalp, palmoplantar area and lower limbs.生物药物对银屑病难治性身体部位(头皮、掌跖部位和下肢)的实际疗效。
J Eur Acad Dermatol Venereol. 2019 Jan;33(1):e22-e23. doi: 10.1111/jdv.15119. Epub 2018 Jun 26.
8
Baseline patients' characteristics as predictors for therapeutic survival and response in patients with psoriasis on biological treatments.基线患者特征作为银屑病生物治疗患者治疗生存和反应的预测指标。
Australas J Dermatol. 2018 Nov;59(4):e247-e252. doi: 10.1111/ajd.12760. Epub 2018 Jan 8.
9
Experience of Being Young With Psoriasis: Self-Management Support Needs.银屑病青少年患者的患病体验:自我管理支持需求。
Qual Health Res. 2018 Jan;28(1):73-86. doi: 10.1177/1049732317737311.
10
Intentional and Unintentional Medication Non-Adherence in Psoriasis: The Role of Patients' Medication Beliefs and Habit Strength.银屑病患者的故意和非故意药物不依从:患者药物信念和习惯强度的作用。
J Invest Dermatol. 2018 Apr;138(4):785-794. doi: 10.1016/j.jid.2017.11.015. Epub 2017 Nov 26.